BioPharmX (NASDAQ:BPMX) saw an uptick in trading volume on Wednesday following insider buying activity. 1,356,384 shares traded hands during trading, an increase of 445% from the previous session’s volume of 249,006 shares.The stock last traded at $0.31 and had previously closed at $0.28.

Specifically, Director Stephen Morlock purchased 428,571 shares of BioPharmX stock in a transaction dated Monday, November 28th. The shares were bought at an average cost of $0.35 per share, with a total value of $149,999.85. Following the completion of the transaction, the director now directly owns 543,956 shares in the company, valued at approximately $190,384.60. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Separately, HC Wainwright restated a “buy” rating on shares of BioPharmX in a report on Saturday, September 17th.

The company has a 50 day moving average price of $0.29 and a 200 day moving average price of $0.57. The company’s market cap is $9.66 million.

TRADEMARK VIOLATION NOTICE: “BioPharmX (BPMX) Sees Strong Trading Volume After Insider Buying Activity” was first reported by Financial Market News and is owned by of Financial Market News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this news story can be read at http://www.financial-market-news.com/biopharmx-bpmx-sees-strong-trading-volume-after-insider-buying-activity/1211683/.

BioPharmX Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

5 Day Chart for NASDAQ:BPMX

Receive News & Ratings for BioPharmX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPharmX and related companies with MarketBeat.com's FREE daily email newsletter.